(Alliance News) - Syncona Ltd on Wednesday noted positive trial results for a portfolio company's gene therapy aimed at treating people with Gaucher's disease.
The global gaucher and pompe diseases enzyme replacement therapy (ERT) market is poised for remarkable growth, with projections indicating a surge from USD 3.3 billion in 2023 to an impressive USD 6.2 ...